Fredun Pharmaceuticals Ltd

₹ 1,613 -0.12%

19 Mar 2:22 p.m.

About

Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products^[1]

Key Points

Business Overview:^[1]
The company, a subsidiary of the Fredun Group, manufactures pharmaceutical and allopathic formulations including tablets, syrups, capsules, and ointments across therapeutic areas like anti-diabetics, anti-retrovirals, and anti-hypertensives. It has also expanded into dietary and herbal supplements, nutraceuticals, diagnostic kits, and animal healthcare products through group entities Fredun Healthcare Pvt. Ltd. and Fredna Enterprises.

Website BSE

Market Cap ₹ 866 Cr.
Current Price ₹ 1,613
High / Low ₹ 1,999 / 635
Stock P/E 25.4
Book Value ₹ 294
Dividend Yield 0.04 %
ROCE 18.9 %
ROE 15.8 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 61.4% CAGR over last 5 years
Company's median sales growth is 28.9% of last 10 years

Cons

Promoter holding has decreased over last quarter: -5.87%
Debtor days have increased from 85.2 to 142 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
	78	80	62	82	87	118	79	107	103	167	120	145	161
	71	68	54	72	76	107	68	93	89	150	103	123	135
Operating Profit	7	12	8	10	11	11	10	14	13	17	17	22	26
OPM %	9%	15%	12%	12%	12%	9%	13%	13%	13%	10%	14%	15%	16%
	0	0	0	0	0	0	0	0	0	0	0	0	0
Interest	2	4	3	3	4	4	4	5	5	8	7	8	11
Depreciation	1	1	1	1	1	1	1	1	1	1	1	2	2
Profit before tax	5	8	4	6	6	6	6	8	7	8	9	13	14
Tax %	25%	51%	41%	32%	27%	13%	25%	44%	25%	12%	25%	25%	25%
	3	4	2	4	4	5	4	4	5	7	7	10	10
EPS in Rs	7.66	8.58	5.24	8.41	8.98	10.76	8.75	9.04	11.29	14.97	14.34	20.61	19.53
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
	21	25	42	57	60	97	113	134	222	275	348	456	593
	20	24	38	53	54	87	104	126	208	247	310	401	510
Operating Profit	1	2	4	3	6	10	8	8	14	28	38	55	83
OPM %	7%	7%	9%	6%	10%	11%	7%	6%	6%	10%	11%	12%	14%
	0	0	1	2	0	0	1	1	2	2	1	0	0
Interest	1	1	2	2	2	3	4	4	5	9	14	22	33
Depreciation	1	1	1	1	1	1	2	2	2	3	4	4	6
Profit before tax	0	1	2	2	3	6	2	3	9	18	21	28	44
Tax %	47%	52%	42%	36%	34%	28%	24%	37%	26%	38%	27%	26%
	0	0	1	1	2	4	2	2	6	11	16	21	34
EPS in Rs	1.02	1.11	4.55	6.08	5.11	11.18	4.76	5.04	14.30	23.85	33.22	44.07	69.45
Dividend Payout %	0%	0%	13%	10%	12%	6%	14%	14%	5%	3%	2%	2%

Compounded Sales Growth
10 Years:	34%
5 Years:	32%
3 Years:	27%
TTM:	46%

Compounded Profit Growth
10 Years:	54%
5 Years:	61%
3 Years:	49%
TTM:	81%

Stock Price CAGR
10 Years:	%
5 Years:	29%
3 Years:	24%
1 Year:	133%

Return on Equity
10 Years:	13%
5 Years:	13%
3 Years:	15%
Last Year:	16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	2	2	2	2	3	4	4	4	4	5	5	5	5
Reserves	0	0	1	2	19	35	37	39	64	92	117	137	153
	7	9	16	21	10	19	35	40	53	87	106	166	171
	8	11	24	30	47	47	65	79	66	74	81	179	136
Total Liabilities	18	23	43	56	79	105	141	162	187	257	308	487	464
	7	8	15	16	16	31	31	30	32	39	47	53	65
CWIP	0	1	0	4	11	0	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	0	0	0	0	1	2	2
	11	14	29	36	52	74	110	131	155	218	260	433	397
Total Assets	18	23	43	56	79	105	141	162	187	257	308	487	464

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	-1	2	3	4	17	1	-11	0	-2	-14	-0	-29
	-2	-3	-6	-7	-8	-5	-1	-1	-4	-9	-8	-6
	2	1	3	3	-8	4	14	-1	7	25	6	38
Net Cash Flow	-0	0	1	-1	1	0	2	-2	1	1	-2	3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	59	75	98	131	94	67	126	112	148	46	68	142
Inventory Days	107	102	140	68	170	249	227	242	96	264	246	265
Days Payable	152	167	221	224	360	205	208	215	101	104	88	160
Cash Conversion Cycle	14	11	17	-24	-96	110	145	139	144	205	225	247
Working Capital Days	-44	-54	-44	-39	42	66	65	116	126	97	92	76
ROCE %	14%	14%	25%	18%	16%	21%	10%	10%	13%	18%	17%	19%

Insights

In beta

Mar 2007

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Daily Compression Capacity (Tablets)
Million Units

	x.xx	xx.xx	x.xx	xx.xx	x.xx	xx.xx	xx.xx		x.xx	xx.xx	x.xx
	x,xxx	x,xxx	x,xxx	x,xxx	xx,xxx	xx,xxx	xx,xxx		xx,xxx	xx,xxx	x,xxx
	xx	xx		xx	xx	xx	xx	xx	xx	xx	xx
xx	xxx	xxx		xxx	xxx			xxx	x,xxx	xxx	xxx
					xxx	xxx		xxx	x,xxx	x,xxx	x,xxx
					xx,xxx	xx,xxx			xxx,xxx	xxx,xxx	xx,xxx
							x	xx	xx	xxx

Please log in to see hidden values.

Daily Granulation Capacity (Tablets)
Kgs

Number of International Markets Present
Countries

Number of Registered Products Globally
Count

Products Under Registration Globally
Count

Daily Topicals Capacity
Tubes

Pet Care (Freossi) Product Portfolio
SKUs

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Feb 2026
	49.62%	49.31%	49.16%	49.17%	49.17%	48.93%	48.93%	48.93%	48.93%	48.93%	43.06%	43.06%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.46%	1.06%
	1.64%	1.60%	1.60%	1.60%	1.60%	1.59%	1.59%	1.59%	1.59%	1.61%	3.48%	2.89%
	48.74%	49.08%	49.24%	49.24%	49.23%	49.47%	49.47%	49.47%	49.49%	49.46%	53.00%	52.99%
No. of Shareholders	4,625	6,313	6,837	7,507	7,511	8,018	8,121	7,976	7,906	8,120	8,765	8,443

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Feb 2026
	74.44%	54.04%	52.04%	52.04%	52.04%	51.27%	50.15%	49.17%	48.93%	43.06%
	0.00%	0.00%	1.68%	1.23%	0.00%	0.00%	0.00%	0.00%	0.00%	1.06%
	3.19%	2.19%	1.88%	1.88%	1.88%	1.69%	1.65%	1.60%	1.59%	2.89%
	22.37%	43.77%	44.40%	44.85%	46.08%	47.04%	48.20%	49.24%	49.47%	52.99%
No. of Shareholders	509	562	1,046	1,478	1,992	3,620	4,521	7,507	7,976	8,443

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Feb 2026
Transcript
PPT
Nov 2025
Transcript
PPT
REC
Aug 2025
Transcript
PPT
REC
Jun 2025

Transcript

AI Summary
PPT
Jun 2025

Transcript

AI Summary
PPT
Feb 2023

Transcript

AI Summary
PPT
Jun 2019

Transcript

AI Summary
PPT